RHBC
TEVA icon

R.H. Bluestein & Co’s Teva Pharmaceuticals TEVA Stock Holding History

R.H. Bluestein & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,300
Closed -$269K – 337
2017
Q3 		$269K Buy
+15,300
New +$344K 0.01% 266
2017
Q2 		– Sell
-11,600
Closed -$372K – 335
2017
Q1 		$372K Hold
11,600
– – 0.02% 192
2016
Q4 		$421K Sell
11,600
-1,779
-13% -$71K 0.03% 140
2016
Q3 		$616K Sell
13,379
-2,921
-18% -$152K 0.04% 91
2016
Q2 		$819K Sell
16,300
-4,100
-20% -$218K 0.06% 71
2016
Q1 		$1.09M Buy
20,400
+400
+2% +$23.5K 0.08% 66
2015
Q4 		$1.31M Hold
20,000
– – 0.08% 63
2015
Q3 		$1.13M Hold
20,000
– – 0.08% 70
2015
Q2 		$1.18M Hold
20,000
– – 0.07% 83
2015
Q1 		$1.25M Hold
20,000
– – 0.08% 81
2014
Q4 		$1.15M Sell
20,000
-53,900
-73% -$3M 0.07% 93
2014
Q3 		$3.97M Buy
73,900
+36,700
+99% +$1.94M 0.25% 55
2014
Q2 		$1.95M Buy
37,200
+7,200
+24% +$368K 0.12% 65
2014
Q1 		$1.58M Buy
30,000
+15,000
+100% +$693K 0.1% 70
2013
Q4 		$601K Hold
15,000
– – 0.04% 174
2013
Q3 		$567K Sell
15,000
-430
-3% -$16.8K 0.04% 164
2013
Q2 		$605K Buy
+15,430
New +$601K 0.05% 148

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

R.H. Bluestein & Co's TEVA Position: Q4 2017 in Review

R.H. Bluestein & Co sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 15,300 shares — an estimated $269K sold.

R.H. Bluestein & Co first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $3.97M in Q3 2014. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • R.H. Bluestein & Co reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • R.H. Bluestein & Co sold 15,300 Teva Pharmaceuticals shares in Q4 2017, an estimated $269K.
  • R.H. Bluestein & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • R.H. Bluestein & Co's Teva Pharmaceuticals position peaked at $3.97M in Q3 2014.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on R.H. Bluestein & Co's 13F filing for Q4 2017, filed 13 Feb 2018.